"In epithelial ovarian cancer (EOC), miRNA-expression profiles have been
described that are associated with different characteristics of ovarian
cancer (eg, tumour subtype, stage, histological grade, prognosis, and
therapy resistance)........However, these studies should focus on pure histotypes, as EOC is
thought to be a heterogeneous disease in which some histotypes are
completely different entities all together, with different response
outcomes to standard treatment. Another confounding factor for
prognostic marker discovery might be exposure to platinum-based
combination chemotherapy. Preferably, only patients who did not receive
chemotherapy should be analysed for PFS. Because stage I EOC samples are
relatively rare, we encourage additional studies to be done by
international consortia. With the above-mentioned considerations in
mind, valid miRNA biomarkers will be identified that can be of use in
the clinic, and help to personalise treatment."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.